Barclays upgrades Inditex citing US growth potential and GLP-1 drug market tailwinds

Barclays issued a double upgrade for Inditex, projecting strong performance for its sub-brands and identifying a unique growth catalyst in the US market linked to the prevalence of anti-obesity drugs. The analyst report suggests that changing consumer demographics and habits associated with GLP-1 usage may drive increased demand for the retailer's apparel offerings.